NEWS: Regen BioPharma, Inc. Begins Program to Determine the 3-Dimensional Crystal Structure of NR2F6
PR Newswire PR NewswireOctober 23, 2017
Structures With and Without Small Molecules to be Determined
SAN DIEGO, October 23, 2017 /PRNewswire/ --
Regen BioPharma Inc. (RGBP) and (RGBPP) has begun a program to determine the 3-dimensional structure of NR2F6 both with and without the Company's proprietary small molecule drugs bound to it. The Company recently reported that it has identified key structural elements in small molecules that make them active and specific towards the NR2F6 target. The object of this structure-determination program is to shed light on exactly how the small molecules bind to and modulate NR2F6 activity.
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity.
"Understanding exactly how our small molecules bind to and modulate NR2F6 activity at the molecular level is extremely important," says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen. "Nothing can substitute for the clear picture an X-ray crystal structure can potentially provide. Although producing such a structure is not assured, we do expect to have some preliminary results in about 5 months. My goal is to have at least three structures solved: 1) the protein alone, 2) the protein with our lead agonist and 3) the protein with our lead antagonist."
"We continue to push our programs in order to have all the best possible data at hand," says David Koos, Ph.D., Chairman & CEO Regen BioPharma Inc. "Having a crystal structure of NR2F6, particularly one with our compound bound to it, will open new avenues for additional drugs, will answer specific mechanistic questions and will further reduce the risk in the overall NR2F6 program."
AI
